المؤلفون: Valentina Zanuso, Tamsin Nash, Raffaella Casolino, Gregory Armstrong, Ona Pallise, Jen Milne, Chiara Braconi

المصدر: BMC Cancer, Vol 24, Iss 1, Pp 1-10 (2024)

مصطلحات موضوعية: Cholangiocarcinoma, Biliary cancer, Genomic profiling, Systemic treatment, Chemotherapy, Scotland, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1471-2407Test

الوصول الحر: https://doaj.org/article/aea977adc0ee461189dd90aa214ea7c3Test

المؤلفون: Hiroyuki Hakoda, Yoshikuni Kawaguchi, Yoichi Miyata, Junichi Togashi, Motoki Nagai, Yoshio Suzuki, Yukihiro Nomura

المصدر: Case Reports in Gastroenterology, Vol 18, Iss 1, Pp 129-135 (2024)

مصطلحات موضوعية: adenosquamous cell carcinoma, ampullary cancer, biliary cancer, pancreatic cancer, hepatobiliary pancreatic surgery, Diseases of the digestive system. Gastroenterology, RC799-869

وصف الملف: electronic resource

العلاقة: https://beta.karger.com/Article/FullText/537900Test; https://doaj.org/toc/1662-0631Test

الوصول الحر: https://doaj.org/article/1f21ebb24e9f4c7288fb05a5adcdc139Test

المؤلفون: Christina Hartwig, Jan Müller, Hagen Klett, Dina Kouhestani, Anke Mittelstädt, Anna Anthuber, Paul David, Maximilian Brunner, Anne Jacobsen, Karolina Glanz, Izabela Swierzy, Lotta Roßdeutsch, Bettina Klösch, Robert Grützmann, Timo Wittenberger, Kai Sohn, Georg F. Weber

المصدر: Molecular Cancer, Vol 23, Iss 1, Pp 1-7 (2024)

مصطلحات موضوعية: cfDNA, Next-generation sequencing, Pancreato-biliary cancer, Pancreatitis, Non-invasive diagnostics, Hybridization and capture, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1476-4598Test

الوصول الحر: https://doaj.org/article/9a79fe14ad154077ba918ec5b2bf60e4Test

المؤلفون: E. V. Ledin, V. I. Stolyarov, Е. В. Ледин, В. И. Столяров

المصدر: Meditsinskiy sovet = Medical Council; № 22 (2023); 172-180 ; Медицинский Совет; № 22 (2023); 172-180 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: радиоэмболизация, biliary tract adenocarcinomas, biliary cancer, metastatic cancer, durvalumab, tremelimumab, immunotherapy, radioembolization, аденокарциномы желчных путей, билиарный рак, метастатический рак, дурвалумаб, тремелимумаб, иммунотерапия

وصف الملف: application/pdf

العلاقة: https://www.med-sovet.pro/jour/article/view/7990/7078Test; Каприн АД, Старинский ВВ, Шахзадова АО. (ред.). Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена; 2021. 252 с. Режим доступа: https://oncology-association.ru/wp-content/uploads/2022/11/zlokachestvennye-novoobrazovaniya-v-rossii-v-2021-g_zabolevaemost-i-smertnost.pdfTest.; Forner A, Vidili G, Rengo M, Bujanda L, Ponz-Sarvisé M, Lamarca A. Clinical presentation, diagnosis and staging of cholangiocarcinoma. Liver Int. 2019;39(S1):98–107. https://doi.org/10.1111/liv.14086Test.; Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet. 2021;397(10272):428–444. https://doi.org/10.1016/S0140-6736Test(21)00153-7.; EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma. J Hepatol. 2023;79(1):181–208. https://doi.org/10.1016/j.jhep.2023.03.010Test.; Neumann UP, Schmeding M. Role of surgery in cholangiocarcinoma: From resection to transplantation. Best Pract Res Clin Gastroenterol. 2015;29(2):295–308. https://doi.org/10.1016/j.bpg.2015.02.007Test.; Neuzillet C, Emery C, Teissier C, Bouée S, Lièvre A. Patient healthcare trajectories of intrahepatic cholangiocarcinoma in France: A nationwide retrospective analysis. Lancet Reg Health Eur. 2022;15:100324. https://doi.org/10.1016/j.lanepe.2022.100324Test.; Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557–588. https://doi.org/10.1038/s41575-020-0310-zTest.; Ali H, Tedder B, Waqar SH, Mohamed R, Cate EL, Ali E. Changing incidence and survival of intrahepatic cholangiocarcinoma based on Surveillance, Epidemiology, and End Results Database (2000–2017). Ann Hepatobiliary Pancreat Surg. 2022;26(3):235–243. https://doi.org/10.14701/ahbps.21-173Test.; Woods E, Le D, Jakka BK, Manne A. Changing Landscape of Systemic Therapy in Biliary Tract Cancer. Cancers. 2022;14(9):2137. https://doi.org/10.3390/cancers14092137Test.; Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A et al. Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. N Engl J Med. 2010;362(14):1273–1281. https://doi.org/10.1056/NEJMoa0908721Test.; Moris D, Palta M, Kim C, Allen PJ, Morse MA, Lidsky ME. Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin. 2023;73(2):198–222. https://doi.org/10.3322/caac.21759Test.; Abou-Alfa GK, Macarulla T, Milind MJ, Kelley RK, Lubner SJ, Adeva J et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(6):796–807. https://doi.org/10.1016/S1470-2045Test(20)30157-1.; Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB et al. Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma. N Engl J Med. 2023;388(3):228–239. https://doi.org/10.1056/NEJMoa2206834Test.; Gupta A, Kurzrock R, Adashek JJ. Evolution of the Targeted Therapy Landscape for Cholangiocarcinoma: Is Cholangiocarcinoma the “NSCLC” of GI Oncology? Cancers (Basel). 2023;15(5):1578. https://doi.org/10.3390/cancers15051578Test.; Ricci AD, D’Alessandro R, Rizzo A, Schirizzi A, Vallarelli S, Ostuni C et al. Durvalumab in advanced cholangiocarcinoma: is someone knocking down the door? Immunotherapy. 2023;15(7):477–486. https://doi.org/10.2217/imt-2022-0301Test.; Oh DY, He AW, Qin S, Chen LT, Okusaka T, Vogel A et al. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evid. 2022;1(8):EVIDoa2200015. https://doi.org/10.1056/EVIDoa2200015Test.; Chuaysri C, Thuwajit P, Paupairoj A, Chau-In S, Suthiphongchai T, Thuwajit C. Alpha-smooth muscle actin-positive fibroblasts promote biliary cell proliferation and correlate with poor survival in cholangiocarcinoma. Oncol Rep. 2009;21(4):957–969. https://doi.org/10.3892/or_00000309Test.; Fabris L, Perugorria MJ, Mertens J, Björkström NK, Cramer T, Lleo A et al. The tumour microenvironment and immune milieu of cholangiocarcinoma. Liver Int. 2019;39(S1):63–78. https://doi.org/10.1111/liv.14098Test.; Zhou G, Sprengers D, Mancham S, Erkens R, Boor PC, Beek AA et al. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules. J Hepatol. 2019;71(4):753–762. https://doi.org/10.1016/j.jhep.2019.05.026Test.; Sabbatino F, Villani V, Yearley JH, Deshpande V, Cai L, Konstantinidis IT et al. PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma. Clin Cancer Res. 2016;22(2):470–478. https://doi.org/10.1158/1078-0432.CCR-15-0715Test.; Yu X, Zhu L, Wang T, Chen J. Immune microenvironment of cholangiocarcinoma: Biological concepts and treatment strategies. Front Immunol. 2023;14:1037945. https://doi.org/10.3389/fimmu.2023.1037945Test.; Heinhuis KM, Ros W, Kok M, Steeghs N, Beijnen JH, Schellens JHM. Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. Ann Oncol. 2019;30(2):219–235. https://doi.org/10.1093/annonc/mdy551Test.; Vanpouille-Box C, Formenti SC, Demaria S. Toward Precision Radiotherapy for Use with Immune Checkpoint Blockers. Clin Cancer Res. 2018;24(2):259–265. https://doi.org/10.1158/1078-0432.CCR-16-0037Test.; Liu W, Fowler D, Smith P, Dalgleish AG. Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer. 2010;102(1):115–123. https://doi.org/10.1038/sj.bjc.6605465Test.; Sawasdee N, Thepmalee C, Sujjitjoon J, Yongpitakwattana P, Junking M, Poungvarin N et al. Gemcitabine enhances cytotoxic activity of effector T-lymphocytes against chemo-resistant cholangiocarcinoma cells. Int Immunopharmacol. 2020;78:106006. https://doi.org/10.1016/j.intimp.2019.106006Test.; Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–413. https://doi.org/10.1126/science.aan6733Test.; Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353–1365. https://doi.org/10.1016/S1470-2045Test(20)30445-9.; Merters J, Lamarca A. Integrating cytotoxic, targeted and immune therapies for cholangiocarcinoma. J Hepatol. 2023;78(3):652–657. https://doi.org/10.1016/j.jhep.2022.11.005Test.; Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11(11):3887–3895. https://doi.org/10.1002/j.1460-2075.1992.tb05481.xTest.; Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007;19(7):813–824. https://doi.org/10.1093/intimm/dxm057Test.; Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002;99(19):12293–12297. https://doi.org/10.1073/pnas.192461099Test.; Nishimura H, Minato N, Nakano T, Honjo T. Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses. Int Immunol. 1998;10(10):1563–1572. https://doi.org/10.1093/intimm/10.10.1563Test.; Tan S, Liu K, Chai Y, Zhang CH, Gao S, Gao GF, Qi J. Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab. Protein Cell. 2018;9(1):135–139. https://doi.org/10.1007/s13238-017-0412-8Test.; Ioka T, Ueno M, Oh DY, Fujiwara Y, Chen JS, Doki Y et al. Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC). J Clin Oncol. 2019;37(4):387–387. https://doi.org/10.1200/JCO.2019.37.4_suppl.387Test.; Oh DY, Lee KH, Lee DW, Yoon J, Kim TY, Bang JH et al. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study. Lancet Gastroenterol Hepatol. 2022;7(6):522–532. https://doi.org/10.1016/S2468-1253Test(22)00043-7.; Vogel А, Boeck S, Waidmann О, Bitzer М, Wenzel Р, Belle S et al. 52MO A randomized phase II trial of durvalumab and tremelIMUmab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naïve patients with CHolangio- and gallbladdEr Carcinoma (IMMUCHEC). Ann Oncol. 2022;33(7):563. https://doi.org/10.1016/j.annonc.2022.07.080Test.; Oh D, He AR, Qin S, Chen L, Okusaka Т, Vogel А et al. Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC). Ann Oncol. 2022;33(9):1462–1463. https://doi.org/10.1016/j.annonc.2022.10.114Test.; Valle JW, Qin S, Antonuzzo L, Tougeron D, Lee C, Tan BJ, Ikeda М. Impact of mutation status on efficacy outcomes in TOPAZ-1: A phase III study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+GC) in advanced biliary tract cancer (BTC). Ann Oncol. 2022;33(9):1454–1484. https://doi.org/10.1016/annonc/annonc1123Test.; Rimini M, Fornaro L, Lonardi S, Niger M, Lavacchi D, Pressiani T et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data. Liver Int. 2023;43(8):1803–1812. https://doi.org/10.1111/liv.15641Test.; Vogel A, Bridgewater J, Edeline J, Kelley RK, Klümpen HJ, Malka D et al. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(2):127–140. https://doi.org/10.1016/j.annonc.2022.10.506Test.; Бредер ВВ, Базин ИС, Балахнин ПВ, Виршке ЭР, Косырев ВЮ, Ледин ЕВ и др. Практические рекомендации по лекарственному лечению больных злокачественными опухолями печени и желчевыводящей системы. Злокачественные опухоли. 2022;12(3s2-1):467–529. https://doi.org/10.18027/2224-5057-2022-12-3s2-467-529Test.; Kim Y, Ok B, Park I, Ryoo BY, Kim KP, Yoo C. Randomized phase 2 study of maintenance olaparib vs olaparib plus durvalumab for DNA damage repair (DDR) gene mutated unresectable or metastatic biliary tract cancer (BTC) with durable response to first-line platinum-based chemotherapy: OPTIMUM trial. J Clin Oncol. 2023;41(16):4180. https://doi.org/10.1200/JCO.2023.41.16_suppl.TPS4180Test.; Goetze TO, Kochen L, Vortmeyer D, Al-Batran SE, Habibzada T, Brunner M et al. ADJUBIL: A phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in adjuvant situation for biliary tract cancer. J Clin Oncol. 2023;41(16):4187. https://doi.org/10.1200/JCO.2023.41.16_suppl.TPS4187Test.; Zhu AX, Macarulla T, Javle MM, Kelley K, Lubner SJ, Adevaet J et al. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial. JAMA Oncol. 2021;7(11):1669–1677. https://doi.org/10.1001/jamaoncol.2021.3836Test.; Edeline J, Touchefeu Y, Guiu B, Farge O, Tougeron D, Baumgaertner I et al. Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol. 2020;6(1):51–59. https://doi.org/10.1001/jamaoncol.2019.3702Test.; https://www.med-sovet.pro/jour/article/view/7990Test

الإتاحة: https://doi.org/10.21518/ms2023-438Test
https://doi.org/10.1111/liv.14086Test
https://doi.org/10.1016/S0140-6736Test(21)00153-7
https://doi.org/10.1016/j.jhep.2023.03.010Test
https://doi.org/10.1016/j.bpg.2015.02.007Test
https://doi.org/10.1016/j.lanepe.2022.100324Test
https://doi.org/10.1038/s41575-020-0310-zTest
https://doi.org/10.14701/ahbps.21-173Test
https://doi.org/10.3390/cancers14092137Test
https://doi.org/10.1056/NEJMoa0908721Test

المؤلفون: Hartwig, Christina, Müller, Jan, Klett, Hagen, Kouhestani, Dina, Mittelstädt, Anke, Anthuber, Anna, David, Paul, Brunner, Maximilian, Jacobsen, Anne, Glanz, Karolina, Swierzy, Izabela, Roßdeutsch, Lotta, Klösch, Bettina, Grützmann, Robert, Wittenberger, Timo, Sohn, Kai, Weber, Georg F.

مصطلحات موضوعية: cfDNA, cfMBD-Seq, DMRs, Hybridization and capture, IPMN, Methylation, Next-generation sequencing, Non-invasive diagnostics, Pancreatitis, Pancreato-biliary cancer

العلاقة: Molecular cancer; https://publica.fraunhofer.de/handle/publica/462491Test

الإتاحة: https://doi.org/10.1186/s12943-024-01943-xTest
https://publica.fraunhofer.de/handle/publica/462491Test

المؤلفون: Anurag Lavekar, Saurabh Mukewar

المصدر: Journal of Digestive Endoscopy, Vol 14, Iss 01, Pp 041-048 (2023)

مصطلحات موضوعية: biliary cancer, biliary rfa, pancreatic cystic neoplasm, pancreatic neuroendocrine tumor, pancreatic rfa, Diseases of the digestive system. Gastroenterology, RC799-869

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/0976-5042Test; https://doaj.org/toc/0976-5050Test

الوصول الحر: https://doaj.org/article/f8f697a67aba449186a9f3716aa5777bTest

المؤلفون: David P. Cosgrove, Emily S. Reese, Nicole M. Fulcher, Sarah S. Bobiak, Francois‐Xavier Lamy, Arthur Allignol, Marley Boyd, Seyed H. Mahmoudpour

المصدر: Cancer Medicine, Vol 12, Iss 4, Pp 4195-4205 (2023)

مصطلحات موضوعية: bile duct cancer, biliary cancer, chemotherapy, cholangiocarcinoma, gallbladder cancer, second line, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2045-7634Test

الوصول الحر: https://doaj.org/article/10f58cd416f74acbbc57c8e425ae1b6dTest

المؤلفون: Cami N. Christopher, Dong-Woo Kang, Rebekah L. Wilson, Paola Gonzalo-Encabo, Salvatore Ficarra, Diane Heislein, Christina M. Dieli-Conwright

المصدر: Nutrients, Vol 15, Iss 24, p 5044 (2023)

مصطلحات موضوعية: physical activity, exercise, nutrition, prehabilitation, hepato-pancreato-biliary cancer, liver cancer, Nutrition. Foods and food supply, TX341-641

وصف الملف: electronic resource

العلاقة: https://www.mdpi.com/2072-6643/15/24/5044Test; https://doaj.org/toc/2072-6643Test

الوصول الحر: https://doaj.org/article/9b00e833edbc4f8d96d2933d5e537012Test

المؤلفون: Paula Villalba Cuesta, Mercedes Avedillo Ruidiaz, Eva Ruiz Hispán, Raquel Fuentes Mateos, Angela Lamarca

المصدر: Cancers, Vol 15, Iss 23, p 5543 (2023)

مصطلحات موضوعية: advanced biliary cancer, cholangiocarcinoma, chemotherapy, second line, review, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://www.mdpi.com/2072-6694/15/23/5543Test; https://doaj.org/toc/2072-6694Test

الوصول الحر: https://doaj.org/article/e7da10c10bd34ab2b1a86b2e5d0d38a2Test

المؤلفون: Kim, Richard D, McDonough, Shannon, El-Khoueiry, Anthony B, Bekaii-Saab, Tanios S, Stein, Stacey M, Sahai, Vaibhav, Keogh, George P, Kim, Edward J, Baron, Ari D, Siegel, Abby B, Barzi, Afsaneh, Guthrie, Katherine A, Javle, Milind, Hochster, Howard

مصطلحات موضوعية: Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Digestive Diseases, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Antineoplastic Combined Chemotherapy Protocols, Biliary Tract Neoplasms, Capecitabine, Female, Fluorouracil, Humans, Male, Middle Aged, Pyridones, Pyrimidinones, Advanced biliary cancer, MEK inhibitor, 5-Fluorouracil, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/89d2d90nTest